282 related articles for article (PubMed ID: 25074979)
21. Function of RasGRP3 in the formation and progression of human breast cancer.
Nagy Z; Kovács I; Török M; Tóth D; Vereb G; Buzás K; Juhász I; Blumberg PM; Bíró T; Czifra G
Mol Cancer; 2014 Apr; 13():96. PubMed ID: 24779681
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.
Dokmanovic M; Wu Y; Shen Y; Chen J; Hirsch DS; Wu WJ
Cancer Biol Ther; 2014 Aug; 15(8):1029-41. PubMed ID: 24835103
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.
Hermes M; Schormann W; Brulport M; Uhlemann K; Lupatsch F; Horn LC; Schumann A; Allgaier C; Weishaupt M; Engeland K; Müller GA; Mössner J; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Lausch E; Prawitt D; Wilhelm C; Hengstler JG
Br J Cancer; 2008 May; 98(9):1525-32. PubMed ID: 18454161
[TBL] [Abstract][Full Text] [Related]
24. MDM2-dependent Sirt1 degradation is a prerequisite for Sirt6-mediated cell death in head and neck cancers.
Park JJ; Hah YS; Ryu S; Cheon SY; Won SJ; Lee JS; Hwa JS; Seo JH; Chang HW; Kim SW; Kim SY
Exp Mol Med; 2021 Mar; 53(3):422-431. PubMed ID: 33727672
[TBL] [Abstract][Full Text] [Related]
25. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
26. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
27. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
Gayle SS; Arnold SL; O'Regan RM; Nahta R
Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
[TBL] [Abstract][Full Text] [Related]
29. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
[TBL] [Abstract][Full Text] [Related]
30. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
31. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Clark AS; West K; Streicher S; Dennis PA
Mol Cancer Ther; 2002 Jul; 1(9):707-17. PubMed ID: 12479367
[TBL] [Abstract][Full Text] [Related]
32. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
34. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
Qiu N; He YF; Zhang SM; Zhan YT; Han GD; Jiang M; He WX; Zhou J; Liang HL; Ao X; Xia HM; Li J; Yang YY; He ZM; Zou ZZ; Li HS
Cancer Lett; 2019 Nov; 464():25-36. PubMed ID: 31461670
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Miller TW; Forbes JT; Shah C; Wyatt SK; Manning HC; Olivares MG; Sanchez V; Dugger TC; de Matos Granja N; Narasanna A; Cook RS; Kennedy JP; Lindsley CW; Arteaga CL
Clin Cancer Res; 2009 Dec; 15(23):7266-76. PubMed ID: 19934303
[TBL] [Abstract][Full Text] [Related]
36. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
[TBL] [Abstract][Full Text] [Related]
37. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
[TBL] [Abstract][Full Text] [Related]
38. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
39. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
[TBL] [Abstract][Full Text] [Related]
40. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
